Since 2016, multiple scientific journals have established a connection between Ozempic and acute gallbladder disease, gallstones, and inflammation
Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management
Photo Credit: Applied Nutrition plc
Weight loss of approximately 25% was maintained for up to ten years post-surgery
You're being asked to consider a botanical formula without knowing what botanicals are in it
No new safety concerns were identified for IcoSema in this trial, and the safety profile for IcoSema reflected that of the respective mono-components